EN2: A novel prostate cancer biomarker

Biomarkers in Medicine

Volumn 7, Issue 6, 2013, Pages 893-901

  Mcgrath, Sophie E ^a   Michael, Agnieszka ^a   Morgan, Richard ^a   Pandha, Hardev ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

biomarker; engrailed 2; prostate cancer; significant disease

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EN2 PROTEIN; GELATINASE B; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; MATRIX METALLOPROTEINASE; PCA3; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

AREA UNDER THE CURVE; CANCER RISK; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC VALUE; DISEASE MARKER; EN2 GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FUSION GENE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HUMAN; ONCOGENE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME; URINALYSIS;

BRCA1 PROTEIN; BRCA2 PROTEIN; HOMEODOMAIN PROTEINS; HUMANS; MALE; NERVE TISSUE PROTEINS; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84889586462     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.115     Document Type: Review

References (87)

1. Siegel R, Desantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62(4), 220-241 (2012).
2. Van Der Kwast TH, Roobol MJ. Defining the threshold for significant versus insignificant prostate cancer. Nat. Rev. Urol. 10(8), 473-482 (2013).
3. Marshall Jr. Diet and prostate cancer prevention. World J. Urol. 30(2), 157-165 (2012).
4. Kote-Jarai Z, Leongamornlert D, Saunders E et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients. Br. J. Cancer 105(8), 1230-1234 (2011).
5. Leongamornlert D, Mahmud N, Tymrakiewicz M et al. Germline BRCA1 mutations increase prostate cancer risk. Br. J. Cancer 106(10), 1697-1701 (2012).
6. Mitra AV, Bancroft EK, Barbachano Y et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. BJU Int. 107(1), 28-39 (2011).
7. Mitra A, Fisher C, Foster CS et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br. J. Cancer 98(2), 502-507 (2008). (Pubitemid 351161242)
8. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat. Rev. Cancer 8(4), 268-278 (2008). (Pubitemid 351430866)
9. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: Blood-based markers. Acta Oncol. 50(Suppl. 1), 61-75 (2011).
10. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 350(22), 2239-2246 (2004).
11. Artibani W. Landmarks in prostate cancer diagnosis: The biomarkers. BJU Int. 110(Suppl. 1), 8-13 (2012).
12. Roddam AW, Duffy MJ, Hamdy FC et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-Analysis. Eur. Urol. 48(3), 386-399; discussion 398-389 (2005).
13. Sokoll LJ, Bruzek DJ, Dua R et al. Short-Term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. Urology 60(4 Suppl. 1), 24-30 (2002).
14. Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 79(1), 104-109 (1997). (Pubitemid 26425514)
15. Carter HB, Morrell CH, Pearson JD et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 52(12), 3323-3328 (1992).
16. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J. Urol. 152(4), 1163-1167 (1994). (Pubitemid 24283458)
17. Carter HB, Pearson JD, Waclawiw Z et al. Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity. Urology 45(4), 591-596 (1995).
18. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J. Clin. Oncol. 27(3), 398-403 (2009).
19. Guazzoni G, Nava L, Lazzeri M et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting. Eur. Urol. 60(2), 214-222 (2011).
20. Oberpenning F, Weining C, Brandt B et al. Combining free and total prostate specific antigen assays from different manufacturers: The pitfalls. Eur. Urol. 42(6), 577-582; discussion 582 (2002).
21. Aly M, Wiklund F, Gronberg H. Early detection of prostate cancer with emphasis on genetic markers. Acta Oncol. 50(Suppl. 1), 18-23 (2011).
22. Kote-Jarai Z, Easton DF, Stanford JL et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium. Cancer Epidemiol. Biomarkers Prev. 17(8), 2052-2061 (2008).
23. Fitzgerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL, Ostrander EA. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: Associations with family history and clinical features. Clin. Cancer Res. 15(9), 3231-3237 (2009).
24. Mehra R, Tomlins SA, Shen R et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 20(5), 538-544 (2007). (Pubitemid 46631996)
25. Ali TZ, Epstein JI. False positive labeling of prostate cancer with high molecular weight cytokeratin: P63 a more specific immunomarker for basal cells. Am. J. Surg. Pathol. 32(12), 1890-1895 (2008).
26. Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am. J. Surg. Pathol. 27(3), 365-371 (2003). (Pubitemid 36245802)
27. Murphy AJ, Hughes CA, Barrett C et al. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res. 67(6), 2893-2898 (2007). (Pubitemid 46548980)
28. Perner S, Hofer MD, Kim R et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum. Pathol. 38(5), 696-701 (2007). (Pubitemid 46560805)
29. Berney DM, Gopalan A, Kudahetti S et al. Ki-67 and outcome in clinically localised prostate cancer: Analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br. J. Cancer 100(6), 888-893 (2009).
30. Khor LY, Bae K, Paulus R et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J. Clin. Oncol. 27(19), 3177-3184 (2009).
31. Whitman EJ, Groskopf J, Ali A et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J. Urol. 180(5), 1975-1978; discussion 1978-1979 (2008).
32. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2(3), 161-174 (2002). (Pubitemid 37328786)
33. Baden J, Green G, Painter J et al. Multicenter evaluation of an investigational prostate cancer methylation assay. J. Urol. 182(3), 1186-1193 (2009).
34. Lintula S, Stenman J, Bjartell A, Nordling S, Stenman UH. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 63(4), 324-329 (2005). (Pubitemid 40664343)
35. Gupta A, Lotan Y, Ashfaq R et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur. Urol. 55(5), 1124-1133 (2009).
36. Shariat SF, Kattan MW, Traxel E et al. Association of pre-And postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin. Cancer Res. 10(6), 1992-1999 (2004). (Pubitemid 38375558)
37. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL 6 and TNF alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer 90(12), 2312-2316 (2004). (Pubitemid 38961893)
38. De Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14(19), 6302-6309 (2008).
39. Lucas SM, Heath EI. Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers. Prostate Cancer 2012, 640968 (2012).
40. Van As NJ, Norman AR, Thomas K et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur. Urol. 54(6), 1297-1305 (2008).
41. Klotz L. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nat. Clin. Pract. Urol. 2(3), 136-142 (2005). (Pubitemid 40812444)
42. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: The Miami experience. BJU Int. 101(2), 165-169 (2008). (Pubitemid 350294039)
43. Auprich M, Chun FK, Ward JF et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur. Urol. 59(1), 96-105 (2011).
44. Ploussard G, Durand X, Xylinas E et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur. Urol. 59(3), 422-429 (2011).
45. Aubin SM, Reid J, Sarno MJ et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial. J. Urol. 184(5), 1947-1952 (2010).
46. Groskopf J, Aubin SM, Deras IL et al. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 52(6), 1089-1095 (2006). (Pubitemid 43794421)
47. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine - A new perspective for detecting prostate cancer. Eur. Urol. 46(2), 182-186; discussion 187 (2004). (Pubitemid 38902733)
48. Fradet Y, Saad F, Aprikian A et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64(2), 311-315; discussion 315-316 (2004).
49. Deras IL, Aubin SM, Blase A et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J. Urol. 179(4), 1587-1592 (2008).
50. Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N. Comparative effectiveness review: Prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J. Urol. 190(2), 389-398 (2013).
51. Schostak M, Schwall GP, Poznanovic S et al. Annexin A3 in urine: A highly specific noninvasive marker for prostate cancer early detection. J. Urol. 181(1), 343-353 (2009).
52. Roy R, Louis G, Loughlin KR et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: Identification of high molecular weight urinary matrix metalloproteinase species. Clin. Cancer Res. 14(20), 6610-6617 (2008).
53. Magi-Galluzzi C, Tsusuki T, Elson P et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71(5), 489-497 (2011).
54. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 13(17), 5103-5108 (2007). (Pubitemid 47502077)
55. Rostad K, Hellwinkel OJ, Haukaas SA et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 117(8), 575-582 (2009).
56. Demichelis F, Fall K, Perner S et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31), 4596-4599 (2007). (Pubitemid 47037039)
57. Day JR, Jones LA, Meyer SE et al. Urinary PCA3 and TMPRSS2:ERG help predict biopsy outcome prior to initial prostate biopsy using a risk group analysis. Presented at: 28th Annual Congress of the European Association of Urology. Milan, Italy, 15-19 March 2013 (Poster 1045).
58. McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell 68(2), 283-302 (1992).
59. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat. Rev. Cancer 10(5), 361-371 (2010).
60. Hanks M, Wurst W, Anson-Cartwright L, Auerbach AB, Joyner AL. Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2. Science 269(5224), 679-682 (1995).
61. Hanks MC, Loomis CA, Harris E et al. Drosophila engrailed can substitute for mouse Engrailed1 function in mid-hindbrain, but not limb development. Development 125(22), 4521-4530 (1998). (Pubitemid 28564295)
62. McGrath SE, Michael A, Pandha H, Morgan R. Engrailed homeobox transcription factors as potential markers and targets in cancer. FEBS Lett. 587(6), 549-554 (2013).
63. Lavezzi AM, Ottaviani G, Mauri M, Terni L, Matturri L. Involvement of the EN 2 gene in normal and abnormal development of the human arcuate nucleus. Int. J. Exp. Pathol. 86(1), 25-31 (2005). (Pubitemid 40204339)
64. Sillitoe RV, Stephen D, Lao Z, Joyner AL. Engrailed homeobox genes determine the organization of Purkinje cell sagittal stripe gene expression in the adult cerebellum. J. Neurosci. 28(47), 12150-12162 (2008).
65. Rissling I, Strauch K, Hoft C, Oertel WH, Moller JC. Haplotype analysis of the engrailed-2 gene in young-onset Parkinson's disease. Neurodegener. Dis. 6(3), 102-105 (2009).
66. Petit E, Herault J, Martineau J et al. Association study with two markers of a human homeogene in infantile autism. J. Med. Genet. 32(4), 269-274 (1995).
67. Wang L, Jia M, Yue W et al. Association of the ENGRAILED 2 (EN2) gene with autism in Chinese Han population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(4), 434-438 (2008). (Pubitemid 351830799)
68. Sen B, Singh AS, Sinha S et al. Family-based studies indicate association of Engrailed 2 gene with autism in an Indian population. Genes Brain Behav. 9(2), 248-255 (2010).
69. Yang P, Shu BC, Hallmayer JF, Lung FW. Intronic single nucleotide polymorphisms of engrailed homeobox 2 modulate the disease vulnerability of autism in a Han Chinese population. Neuropsychobiology 62(2), 104-115 (2010).
70. Joliot A, Trembleau A, Raposo G, Calvet S, Volovitch M, Prochiantz A. Association of Engrailed homeoproteins with vesicles presenting caveolae-like properties. Development 124(10), 1865-1875 (1997). (Pubitemid 27270256)
71. Joliot A, Maizel A, Rosenberg D et al. Identification of a signal sequence necessary for the unconventional secretion of Engrailed homeoprotein. Curr. Biol. 8(15), 856-863 (1998). (Pubitemid 28356044)
72. Maizel A, Bensaude O, Prochiantz A, Joliot A. A short region of its homeodomain is necessary for engrailed nuclear export and secretion. Development 126(14), 3183-3190 (1999). (Pubitemid 29378181)
73. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269(14), 10444-10450 (1994). (Pubitemid 24198241)
74. Martin NL, Saba-El-Leil MK, Sadekova S, Meloche S, Sauvageau G. EN2 is a candidate oncogene in human breast cancer. Oncogene 24(46), 6890-6901 (2005). (Pubitemid 41509412)
75. Morgan R, Bryan RT, Javed S et al. Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. Eur. J. Cancer doi:10.1016/j.ejca.2013.01.019 (2013) (Epub ahead of print).
76. Rauch T, Wang Z, Zhang X et al. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc. Natl Acad. Sci. USA 104(13), 5527-5532 (2007). (Pubitemid 47175714)
77. Lambert SR, Witt H, Hovestadt V et al. Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. Acta Neuropathol. 126(2), 291-301 (2013).
78. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286(5439), 531-537 (1999).
79. Chou WC, Chen CY, Hou HA et al. Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: Comparative analysis of 493 adult patients. Leukemia 23(7), 1303-1310 (2009).
80. Goetz MP, Suman VJ, Ingle JN et al. A two-gene expression ratio of homeobox 13 and interleukin 17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin. Cancer Res. 12(7 Pt 1), 2080-2087 (2006).
81. Jansen MP, Sieuwerts AM, Look MP et al. HOXB13-To-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: A retrospective study. J. Clin. Oncol. 25(6), 662-668 (2007). (Pubitemid 350002921)
82. Bose SK, Bullard RS, Donald CD. Oncogenic role of engrailed-2 (EN-2) in prostate cancer cell growth and survival. Transl. Oncogenom. 3, 37-43 (2008). (Pubitemid 351445322)
83. Gibson W, Green A, Bullard RS, Eaddy AC, Donald CD. Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. Cancer Lett. 248(2), 251-261 (2007). (Pubitemid 46330557)
84. Morgan R, Boxall A, Bhatt A et al. Engrailed-2 (EN2): A tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin. Cancer Res. 17(5), 1090-1098 (2011).
85. Pandha H, Sorensen KD, Orntoft TF et al. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int. 110(6 Pt B), e287-e292 (2012).
86. Pandha H, Javed S, Sooriakumaran P et al. Correlation of urinary engrailed-2 levels to tumour volume and pathological stage in men undergoing radical prostatectomy. J. Cancer Ther. 4, 726-733 (2013).
87. Killick E, Morgan R, Launchbury F et al. Role of engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Sci Rep. 3, 2059 (2013).